Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors
14 mars 2024 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the...
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
08 févr. 2024 08h45 HE
|
International Myeloma Foundation
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 janv. 2024 16h01 HE
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
ExCellThera rencontrera les investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare et participera aux prochaines conférences d'investisseurs
02 janv. 2024 07h00 HE
|
ExCellThera
MONTREAL, 02 janv. 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), un leader mondial des thérapies à base de cellules souches sanguines amplifiées, a annoncé aujourd'hui que ses hauts...
ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences
02 janv. 2024 07h00 HE
|
ExCellThera
ExCellThera senior leaders will be holding investor meetings during JP Morgan Heathcare Conference and participating in upcoming investor conferences.
Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program
29 déc. 2023 18h13 HE
|
Cell BioEngines, Inc.
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood...
ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
12 déc. 2023 07h00 HE
|
ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...
ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting
12 déc. 2023 07h00 HE
|
ExCellThera
50 patients evaluated in Phase 2 studies; ExCellThera’s UM171 showed excellent clinical outcomes for this high-risk leukemia/myelodysplasia cohort
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
12 déc. 2023 05h15 HE
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Be The Match Announces Winners of 2023 NMDP/Be The Match Awards
27 nov. 2023 10h21 HE
|
Be The Match
NMDP/Be The Match® announces the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.